![bcg-publication-2.jpg](https://web-assets.bcg.com/dims4/default/a5baa58/2147483647/strip/true/crop/1440x1440+560+0/resize/146x146!/format/webp/quality/90/?url=http%3A%2F%2Fboston-consulting-group-brightspot.s3.amazonaws.com%2Fa6%2F92%2Fc5bf52bd45ba87a39ae2460373bd%2Fbcg-publication-2.jpg)
Digital Therapeutics 2.0, Part Two: Connecting Users to Outcomes
Once a digital therapeutics (DTx) company has determined the kind of value its software as a medical device (SaMD) provides, it needs to figure out which regulatory and commercialization strategies make the most sense.